Scientists at the Institute of Science Tokyo have developed an intramuscularly delivered mRNA vaccine encoding LRG1 protein that inhibits pathological neovascularization in the retina, effectively suppressing wet age-related macular degeneration (AMD) in mouse models. This vaccine offers a less invasive alternative to current intraocular injections of anti-angiogenic drugs and may provide a long-term therapeutic approach for neovascular eye diseases. The findings were published in Vaccine.